A Novel IgG-IL2 Mutein to Selectively Activate T Regulatory Cells

Time: 2:45 pm
day: Day One

Details:

• Design and development of an IL-2 mutein showing Treg specificity
• Assessment of Treg pharmacology in vitro and in vivo in non-clinical studies
• Path towards clinical development of Treg therapies using IL-2 muteins

Speakers: